A phase IIIB, 12-month, double-blind, double-dummy, randomised, parallel-group, multicentre exacerbation study of SYMBICORT pMDI [budesonide/formoterol] 160/4.5 microg x 2 actuations twice-daily and 80/4.5 microg x 2 actuations twice-daily compared to Formoterol Turbuhaler 4.5 microg x 2 inhalations twice-daily in COPD subjects

Trial Profile

A phase IIIB, 12-month, double-blind, double-dummy, randomised, parallel-group, multicentre exacerbation study of SYMBICORT pMDI [budesonide/formoterol] 160/4.5 microg x 2 actuations twice-daily and 80/4.5 microg x 2 actuations twice-daily compared to Formoterol Turbuhaler 4.5 microg x 2 inhalations twice-daily in COPD subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 16 May 2014

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 27 Oct 2011 Secondary endpoints of assessing effect of treatment long-term health status and symptoms presented at the 77th Annual Meeting of the American College of Chest Physicians: Chest 2011.
    • 26 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Additional locations reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top